IP Library Granted Patent US 8,357,687
Granted Patent B2
US 8,357,687 · App. 13/058,990 · Granted Jan 22, 2013

Macrocyclic indole derivatives useful as hepatitis C virus inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,357,687
App. No.
13/058,990
Granted
Jan 22, 2013
Kind
B2
Abstract

Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Y, R 1 , R 2 , R 4 and n have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

Claims (20)

1. A compound of formula (I),

or a stereochemically isomeric form, or a pharmaceutically acceptable salts, thereof, wherein:

R 1 is selected from hydrogen, halo and C 1-4 alkoxy;

R 2 is selected from C 1-4 alkyl and C 3-6 cycloalkyl;

R 4 is C 3-7 cycloalkyl optionally substituted with halo;

n is 1 or 2;

Y is selected from

a is 2,3,4 or 5;

each b is independently 1 or 2;

R 3 and R 3 ′ are independently selected from hydrogen, C 1-6 alkyl and C 3-6 cycloalkyl.

2. A compound according to claim 1 wherein Y is selected from —N(CH 3 )—(CH 2 ) 4 —N(CH 3 )—,

3. A compound according to claim 1 wherein R 1 is hydrogen or methoxy or fluoro.

4. A compound according to claim 1 wherein R 2 is selected from methyl, ethyl, iso-propyl and cyclopropyl.

5. A compound according to claim 1 wherein R 4 is selected from cyclohexyl and 2-fluorocyclohexyl.

6. A compound according to claim 1 wherein n is 1.

7. A compound according to claim 1 selected from

or a stereochemically isomeric form, or a pharmaceutically acceptable salt, thereof.

8. A pharmaceutical composition comprising a carrier, and as active ingredient an anti-virally effective amount of a compound as claimed in claim 1 .

9. A pharmaceutical composition according to claim 8 , further comprising at least one other anti-HCV compound.

10. A pharmaceutical composition according to claim 8 , further comprising at least one anti HIV compound.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: JANSSEN R & D IRELAND
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 035496/0382 →
CHANGE OF NAME Recorded Apr 15, 2015
From: TIBOTEC PHARMACEUTICALS
To: JANSSEN R&D IRELAND
Reel/Frame 035439/0981 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2012
From: MC GOWAN, DAVID CRAIG; VENDEVILLE, SANDRINE MARIE HELENE; RABOISSON, PIERRE JEAN-MARIE BERNARD; TAHRI, ABDELLAH
To: TIBOTEC BVBA
Reel/Frame 029399/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2012
From: TIBOTEC BVBA
To: TIBOTEC PHARMACEUTICALS
Reel/Frame 029399/0907 →